Clinical Trials Program
临床试验计划
基本信息
- 批准号:10224783
- 负责人:
- 金额:$ 19.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-18 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:Acetic AcidsAddressAdjuvantAffectAgeAlgorithmsAreaBiological AssayCaribbean regionCervicalCervical Cancer ScreeningCervical Intraepithelial NeoplasiaCessation of lifeChildClinicalClinical TrialsColposcopyCommunitiesCorrelative StudyCountryCytologyDetectionDiagnosisDiseaseDominican RepublicDoseEnrollmentGoalsHIVHIV InfectionsHealthHuman Papilloma Virus VaccinationHuman Papilloma Virus VaccineHuman Papilloma Virus-Related Malignant NeoplasmHuman PapillomavirusHuman papilloma virus infectionImaging technologyImmuneImmunopreventionImprove AccessIncidenceInfrastructureInternationalLatin AmericaLeadLesionMalignant NeoplasmsMalignant neoplasm of cervix uteriMeasuresMemory B-LymphocyteMethodsMonoclonal AntibodiesOperative Surgical ProceduresOutcomePap smearPapillomavirus Transforming Protein E6ParticipantPatientsPersonsPeruPopulationPreventionProviderQuality of lifeRandomized Controlled TrialsRecurrenceRegimenResearchResourcesRiskScheduleSirolimusSiteTestingTimeTriageVaccinationVaccinesVisualWomanYouthautomated visual evaluationbasecancer preventioncervical cancer preventiondesignexperiencegirlshigh riskimplementation facilitationimprovedimproved outcomelow and middle-income countriesnew technologynovelovertreatmentpoint of carepremalignantpreventprevention serviceprogramsresponsescreeningstandard of caretreatment strategytumor microenvironment
项目摘要
PROJECT SUMMARY – CLINICAL TRIALS PROGRAM
The goal of the Clinical Trials Program is to address the dual burden of HIV infection and HPV-associated
cervical cancer in Latin America and the Caribbean (LAC). Over 270,000 women die every year of cervical
cancer, and it disproportionately affects women in low- and middle-income countries (LMICs) where
approximately 90% of cervical cancer deaths occur. Peru and the Dominican Republic experience a 3-fold
higher incidence of cervical cancer than the US, as well as high rates of HIV infection, especially in vulnerable
key populations. Women and children living with HIV (WLWH and CLWH) are more likely to have persistent
HPV and high-grade lesions, and they are at higher risk of progression to cancer than HIV-uninfected women.
Addressing the needs of HIV-infected persons at risk for HPV-associated cancers in LMICs involves improving
access to HPV vaccines and more effective screening for and treatment of cervical high-grade lesions. Instead
of replicating the infrastructure needed for screening used in high-resource settings, the clinical trials proposed
here seek to use a new combination of prevention and treatment methods aimed at point-of-care with low-
infrastructure support. We will leverage and strengthen existing research capacity in Seattle and the LAC sites
to explore sustainable solutions that are acceptable to local providers and patients. This includes investigating
optimal HPV vaccine schedules for HIV+ children, assessing new HPV tests and visual imaging technologies
to help clinicians to perform high-quality screening and triage, and testing non-surgical approaches to improve
outcomes of cervical cancer precursors among WLWH. Toward this goal we will conduct three clinical trials:
Trial 1: HPV immunoprevention by vaccination of unexposed children is not optimized for children living with
HIV (CLWH). We will compare longer-term immune (anamnestic) responses among HIV-infected youth (ages
9-13 at the time of enrollment) after 1, 2, or 3 doses of 9-valent HPV vaccine.
Trial 2: Cervical cancer screening and triage among WLWH needs to be optimized to improve detection of
precancerous lesions, reduce overtreatment and facilitate implementation. We will develop a more efficient
algorithm to detect high-grade lesions (CIN2/3) by assessing standard of care (Pap test and visual inspection
with acetic acid), HPV testing, and newer technologies including HPV E6/E7 expression and enhanced visual
inspection (EVA) with automated visual evaluation (AVE), comparable to colposcopy.
Trial 3: Evaluating non-surgical strategies for treatment of high-grade lesions (CIN2/3) diagnosed in
WLWH from Trial 2 in a 2x2 factorial trial of 9-valent HPV vaccine and sirolimus initiated before surgery.
These trials will be framed by the Cervical Cancer Prevention Partnership (C2P2) Center, that brings
together collaborators in Peru, the Dominican Republic, Seattle, with international external scientific and
community advisors. The teams have extensive experience conducting high-quality clinical trials and working
to prevent HPV-related cancers in LMICs and improve health and quality of life for persons living with HIV.
项目总结-临床试验
临床试验计划的目标是解决艾滋病毒感染和HPV相关的双重负担。
宫颈癌在拉丁美洲和加勒比地区(LAC)。每年有超过27万妇女死于宫颈癌
癌症,它不成比例地影响低收入和中等收入国家(LMIC)的妇女,
大约90%的宫颈癌死亡发生。秘鲁和多米尼加共和国经历了3倍
宫颈癌的发病率高于美国,艾滋病毒感染率也很高,特别是在弱势群体中,
关键人群。感染艾滋病毒的妇女和儿童(WLWH和CLWH)更有可能持续感染艾滋病毒。
HPV和高级别病变,并且他们比未感染HIV的妇女进展为癌症的风险更高。
满足低收入国家中有可能患上与人类乳头瘤病毒有关的癌症的艾滋病毒感染者的需要,
获得HPV疫苗以及更有效地筛查和治疗宫颈高度病变。相反
为了复制在高资源环境中使用的筛查所需的基础设施,临床试验提出,
在此寻求使用一种新预防和治疗方法的组合,
基础设施支持。我们将利用和加强西雅图和拉丁美洲和加勒比地区的现有研究能力
探索当地医疗服务提供者和患者都能接受的可持续解决方案。这包括调查
针对HIV阳性儿童的最佳HPV疫苗接种时间表,评估新的HPV检测和视觉成像技术
帮助临床医生进行高质量的筛查和分诊,并测试非手术方法,以改善
WLWH中宫颈癌前体的结果。为了实现这一目标,我们将进行三项临床试验:
试验1:通过接种未暴露儿童的HPV免疫预防对于患有HPV感染的儿童并不是最佳的
艾滋病毒(CLWH)。我们将比较HIV感染青年(年龄)中的长期免疫(回忆)反应,
9-13入组时)接种1、2或3剂9价HPV疫苗后。
试验2:WLWH中的宫颈癌筛查和分诊需要优化,以提高对
癌前病变,减少过度治疗,便于实施。我们将开发一个更有效的
通过评估护理标准(巴氏试验和目视检查)检测高级别病变(CIN 2/3)的算法
HPV检测和更新的技术,包括HPV E6/E7表达和增强视觉
检查(伊娃)与自动视觉评价(AVE),相当于阴道镜。
试验3:评价非手术策略治疗诊断为高级别病变(CIN 2/3),
来自试验2的WLWH,在手术前开始的9价HPV疫苗和西罗莫司的2x2析因试验中。
这些试验将由宫颈癌预防合作伙伴关系(C2 P2)中心进行,该中心将
与秘鲁、多米尼加共和国、西雅图的合作者一起,与国际外部科学和
社区顾问。这些团队在开展高质量临床试验和工作方面拥有丰富的经验
在中低收入国家预防HPV相关癌症,并改善艾滋病毒感染者的健康和生活质量。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARGARET M MADELEINE其他文献
MARGARET M MADELEINE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARGARET M MADELEINE', 18)}}的其他基金
Therapeutic use of HPV L1 Vaccine in Anogenital Neoplasia: VIVA Trial
HPV L1 疫苗在肛门生殖器肿瘤中的治疗用途:VIVA 试验
- 批准号:
9220396 - 财政年份:2017
- 资助金额:
$ 19.96万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 19.96万 - 项目类别:
Research Grant